Cancer recurrence monitoring through genetic testing provides an early warning system for detecting cancer cells that may return after treatment. This proactive approach helps guide treatment decisions and improve long-term outcomes by catching recurrence early.
Genetic testing for recurrence involves analysing blood or tissue samples for specific cancer markers that could indicate the cancer’s return. By tracking these markers, doctors can detect recurrence at a molecular level before it becomes clinically visible, allowing for prompt treatment.
Together, these data layers fuel the RGCC Onconomics Plus, Oncotrace, and Immune Frame panels, turning test results into personalised action plans.
Cancer recurrence monitoring allows for timely interventions when genetic markers suggest a relapse. By detecting recurrence early, it increases the chances of successful treatment and long-term remission, improving survival rates.
Offering personalized tests from RGCC, our mission is to improve treatment outcomes, enhance survival rates, and elevate overall quality of life for those affected by cancer.
© 2025 Neeli Genetics. All Rights Reserved.